Assessing Companion Diagnostics (Cdx) For Reimbursement Within Alberta: Pilot Study Using Health Technology Assessment Of Programmed Death Ligand 1 (Pd-L1) Testing In Non-Small Cell Lung Cancer (Nsclc)